Therefore, following the approval of Exenatide, development of GLP-1 drugs mainly focused on two directions: developing long-acting GLP-1RAs and oral GLP-1RAs (Figure 3)
Unfortunately, given the costs that go into clinical trials and the fact that potentially hundreds of thousands of people are already taking these peptides (so theres already a market driving profit), theres a strong possibility that a new robust clinical trial may never be done on BPC-157
Doctors should counsel their patients to remain alert for symptoms of thyroid tumors, like a lump or swelling in the neck, trouble swallowing, shortness of breath, or persistent hoarseness
Transparency about the supply chain is not an unreasonable expectation when you are injecting compounded medication
Compounded semaglutide is an option under regulated circumstances but requires careful medical supervision and dosing education
A glutathione treatment puts some back